Accessibility Menu
Ocugen Stock Quote

Ocugen (NASDAQ: OCGN)

$1.57
(-3.1%)
-0.05
Price as of October 21, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$1.57
Daily Change
(-3.1%) $0.05
Day's Range
$1.53 - $1.61
Previous Close
$1.57
Open
$1.6
Beta
2.00
Volume
3,007,554
Average Volume
4,446,359
Market Cap
490.3M
Market Cap / Employee
$1.57M
52wk Range
$0.52 - $1.9
Revenue
-
Gross Margin
0.36%
Dividend Yield
N/A
EPS
-$0.2
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Ocugen Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
OCGN+67.31%+390.63%+37.45%-43%
S&P+15.06%+95.03%+14.29%+126%

Ocugen Company Info

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

News & Analysis

The Fool has written over 100 articles on Ocugen.

Financial Health

General

Q2 2025YOY Change
Revenue$1.37M20.3%
Gross Profit$0.45M-20.8%
Gross Margin32.48%-16.9%
Market Cap$283.39M-29.0%
Market Cap / Employee$2.98M0.0%
Employees9546.2%
Net Income-$14.74M3.5%
EBITDA-$12.87M13.5%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$27.01M72.1%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$31.97M527.1%
Short Term Debt$0.85M-51.7%

Ratios

Q2 2025YOY Change
Return On Assets-120.97%-40.2%
Return On Invested Capital-96.74%15.1%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$10.77M-3.3%
Operating Free Cash Flow-$10.73M-8.3%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book15.095.756.9417.8135.11%
Price to Sales58.7257.7545.6159.62-46.73%
Price to Tangible Book Value15.095.756.9517.8135.10%
Enterprise Value to EBITDA-19.31-15.72-14.73-22.48-14.31%
Return on Equity-103.3%-154.0%-249.0%-570.0%374.89%
Total Debt$6.78M$32.50M$31.82M$32.82M378.12%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.